-
Axicabtagene ciloleucel, sold
under the
brand name
Yescarta, is a
medication used for the
treatment for
large B-cell
lymphoma that has
failed conventional...
-
precursor acute lymphoblastic leukemia (B-ALL), and
axicabtagene ciloleucel (
Yescarta),
marketed by Kite
Pharma originally for
diffuse large B-cell lymphoma...
-
adenosine deaminase deficiency (ADA-SCID) 26 May 2016
axicabtagene ciloleucel Yescarta Ex
vitro Kite
pharma large B-cell
lymphoma 18
October 2017 23
August 2018...
- Y | Z
Yaela Yargesa Yasmin Yaz
Ycanth Yellox Yentreve Yervoy Yesafili Yescarta Yimmugo Yocon yohimbine (INN)
Yondelis Yonsa Yorvipath Yosprala Ypozane...
- annum. The
acquisition was
completed in
October 2017, when Kite Pharma's
Yescarta became the
first CAR-T
therapy approved by the FDA for the
treatment of...
-
October 2018.
Retrieved 28 May 2019. "Biogen's Spinraza,
Fosun Kite's
Yescarta and a
controversial Alzheimer's drug: All you need to know
about China's...
- By 2022 this
acquisition had led to two
marketed products for lymphoma:
Yescarta and Tecartus. In November, the
company announced it will
acquire Cell Design...
- 14
December 2019.
Retrieved 13
December 2019.
After Kymriah (Novartis),
Yescarta (Gilead), and
Luxturna (Spark) were
approved in the U.S. in 2017, they...
- was
completed in
October 2017. In
October 2017, Kite Pharma's therapy,
Yescarta (axicabtagene ciloleucel)
became the
first CAR-T
therapy approved by the...
- of the REMS
Program for
another CAR-T therapy,
axicabtagene ciloleucel (
Yescarta).
Brexucabtagene autoleucel was
approved for
medical use in the United...
